Vir Biotechnology, Inc.

VIR ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2017
Revenue $2.7M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $62.5M
SG&A Expense $21.7M
Operating Income $-81.5M
Operating Margin -3,009.5%
Interest Expense
Pretax Income $-80.8M
Income Tax Expense $-10.9M
Net Income $-69.9M
Net Margin -2,579.5%
EPS (Basic) $-8.11
EPS (Diluted) $-8.11
Shares Outstanding (Basic)
Shares Outstanding (Diluted)
Dividends Per Share
← Newer Page 2 of 2 Older →